Anti -Nod2 (Nucleotide Binding Oligomerization Domain 2, NOD2 Protein, NOD2B, Arthrocutaneouveal Granulomatosis, ACUG, BLAU, Caspase Recruitment Domain 15, CARD15, CD, Inflammatory Bowel Disease Protein 1, IBD1, LRR Containing Protein, PSORAS1)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 16; NC_000016.9 (50731050..50766987). Location: 16q21

Polyclonal

Rabbit

Specific for NOD2 protein. Species Crossreactivity: This antibody reacts with human protein. Other species have not been tested. The immunogen used for this antibody production has 100% homology with human and monkey protein.

Affinity Purified
Purified by immunoaffinity chromatography.

Tris-glycine buffer containing 150mM NaCl.

May be stored at 4 degree C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot Store at -20 degree C. Aliquots are stable for at least 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Small volumes of anti-NOD2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

NOD2 is a member of the apoptosis regulating protein family that includes caspase recruitment-domains, as well as Apaf-1 and NOD1. It contains two N-terminal CARDs, a nucleotide binding domain (NBD), and multiple C-terminal leucine-rich repeats (LRRs). NOD2 is expressed in monocytes (whereas NOD1 is expressed in multiple tissues). NOD2 plays a role in regulating NF-kappaB, acts as an intracellular receptor for bacterial lipopolysaccharides, and contributes to inflammatory bowel disease (IBD) and Crohn's disease.

Antibodies; Abs to Apoptosis, Caspase

Western Blot (WB)

Suitable for use in Western Blot.

6,539 Da[Similar Products]

nucleotide-binding oligomerization domain containing 2

nucleotide-binding oligomerization domain-containing protein 2; OTTHUMP00000164224; OTTHUMP00000236088; NOD-like receptor C2; NLR family, CARD domain containing 2; inflammatory bowel disease protein 1; caspase recruitment domain protein 15; nucleotide-binding oligomerization domain 2; caspase recruitment domain family, member 15; caspase recruitment domain-containing protein 15; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain containing 2

NOD2 protein

Q6TDC3_HUMAN

This gene is a member of the Nod1/Apaf-1 family and encodes a protein with two caspase recruitment (CARD) domains and six leucine-rich repeats (LRRs). The protein is primarily expressed in the peripheral blood leukocytes. It plays a role in the immune response to intracellular bacterial lipopolysaccharides (LPS) by recognizing the muramyl dipeptide (MDP) derived from them and activating the NFKB protein. Mutations in this gene have been associated with Crohn disease and Blau syndrome. [provided by RefSeq]

NOD2: Induces NF-kappa-B via RICK (CARDIAK, RIP2) and IKK- gamma. Confers responsiveness to intracellular bacterial lipopolysaccharides (LPS). Defects in NOD2 are the cause of Blau syndrome (BS). BS is a rare autosomal dominant disorder characterized by early-onset granulomatous arthritis, uveitis and skin rash. Defects in NOD2 are a cause of susceptibility to inflammatory bowel disease type 1 (IBD1). IBD1 is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Defects in NOD2 are the cause of sarcoidosis early-onset (EOS). EOS is a form of sarcoidosis manifesting in children younger than 4 years of age. Sarcoidosis is an idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved. Early- onset sarcoidosis is quite rare and has a distinct triad of skin, joint and eye disorders, without apparent pulmonary involvement. Compared with an asymptomatic and sometimes naturally disappearing course of the disease in older children, early-onset sarcoidosis is progressive and in many cases causes severe complications, such as blindness, joint destruction and visceral involvement. 2 isoforms of the human protein are produced by alternative initiation.

Chromosomal Location of Human Ortholog: 16q21

Cellular Component: signalosome; cell surface; protein complex; cytoskeleton; cytoplasm; plasma membrane; cytosol; vesicle

Molecular Function: peptidoglycan binding; protein binding; enzyme binding; CARD domain binding; protein kinase binding; ATP binding; muramyl dipeptide binding

Biological Process: activation of MAPK activity; maintenance of gastrointestinal epithelium; positive regulation of dendritic cell antigen processing and presentation; stress-activated MAPK cascade; response to lipopolysaccharide; toll-like receptor 3 signaling pathway; positive regulation of interleukin-1 beta secretion; positive regulation of interleukin-10 production; negative regulation of interleukin-2 production; activation of NF-kappaB transcription factor; toll-like receptor 5 signaling pathway; positive regulation of gamma-delta T cell activation; positive regulation of phagocytosis; JNK cascade; detection of muramyl dipeptide; cytokine production during immune response; detection of biotic stimulus; toll-like receptor 4 signaling pathway; positive regulation of oxidoreductase activity; positive regulation of interleukin-17 production; negative regulation of interleukin-12 production; positive regulation of T-helper 2 type immune response; positive regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of dendritic cell cytokine production; positive regulation of interleukin-6 production; positive regulation of tumor necrosis factor production; protein oligomerization; toll-like receptor 2 signaling pathway; negative regulation of interleukin-18 production; positive regulation of peptidyl-tyrosine phosphorylation; defense response to Gram-positive bacterium; innate immune response in mucosa; inhibition of NF-kappaB transcription factor; response to muramyl dipeptide; positive regulation of B cell activation; defense response to bacterium; positive regulation of transcription from RNA polymerase II promoter; toll-like receptor 9 signaling pathway; negative regulation of T cell mediated immunity; positive regulation of epithelial cell proliferation; positive regulation of nitric-oxide synthase biosynthetic process; detection of bacterium; positive regulation of interleukin-12 production; positive regulation of JNK cascade; defense response; positive regulation of stress-activated MAPK cascade; toll-like receptor 10 signaling pathway; response to exogenous dsRNA; negative regulation of interferon-gamma production; negative regulation of inflammatory response to antigenic stimulus; positive regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteria; response to nutrient; positive regulation of Notch signaling pathway; positive regulation of humoral immune response mediated by circulating immunoglobulin; MyD88-independent toll-like receptor signaling pathway; negative regulation of toll-like receptor 2 signaling pathway; positive regulation of phosphoinositide 3-kinase activity; negative regulation of tumor necrosis factor production; immunoglobulin production during immune response; MyD88-dependent toll-like receptor signaling pathway; positive regulation of interleukin-1 beta production; regulation of inflammatory response; toll-like receptor signaling pathway; innate immune response

Disease: Psoriatic Arthritis, Susceptibility To; Sarcoidosis, Early-onset; Inflammatory Bowel Disease 1; Blau Syndrome

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.